Mediator MED23 cooperates with RUNX2 to drive osteoblast differentiation and bone development

Citations Over TimeTop 10% of 2016 papers

Abstract

How lineage specifiers are regulated during development is an outstanding question, and the molecular regulation of osteogenic factor RUNX2 remains to be fully understood. Here we report that the Mediator subunit MED23 cooperates with RUNX2 to regulate osteoblast differentiation and bone development. Med23 deletion in mesenchymal stem cells or osteoblast precursors results in multiple bone defects similar to those observed in Runx2(+/-) mice. In vitro, Med23-deficient progenitor cells are refractory to osteoblast differentiation, and Med23 deficiency reduces Runx2-target gene activity without changing Runx2 expression. Mechanistically, MED23 binds to RUNX2 and modulates its transcriptional activity. Moreover, Med23 deficiency in osteoprogenitor cells exacerbates the skeletal abnormalities observed in Runx2(+/-) mice. Collectively, our results establish a genetic and physical interaction between RUNX2 and MED23, suggesting that MED23 constitutes a molecular node in the regulatory network of anabolic bone formation and related diseases.

Related Papers

• → Regulation of Osteoblast Differentiation by Runx2(2009)514 cited
• → Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3(2018)193 cited
• → Runx2: of bone and stretch(2007)133 cited
• → VGLL4 promotes osteoblast differentiation by antagonizing TEADs-inhibited Runx2 transcription(2020)63 cited
• → Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivo(2008)77 cited